Pharmaceutical R&D Informatics Header Image

 

Pharmaceutical R&D Informatics
製薬R&Dインフォマティクス

Drive Precision Medicine through the Digitalization of Pharma R&D
製薬R&Dのデジタル化による精密医療の推進

2025年4月2日〜4日 米国東部標準時(EDT)

製薬業界におけるデータの生成、整理、分析に関する緊急性は衰えていません。実は、新しいテクノロジーを開発し、ニューノーマルにおいてインフラや特別なプロジェクトの開発を加速させたいという要望は、記録的なスピードで高まり続けています。「製薬R&Dインフォマティクス」トラックでは、科学、ビジネス、規制上の要求を満たしながら、効率的なインフォマティクスエコシステムを構築するために、新しいテクノロジーとサービスを通じて、オペレーションを最適化するためのデジタルトランスフォーメーションの取り組みと戦略を探ります。データの整理と分析における新たなトレンド、FAIR原則の役割、柔軟なデータクエリをサポートするインフラについて説明します。このプログラムでは、柔軟なモダリティ、インフラを通じてこれをサポートする方法、大規模言語モデル、ChatGPT、AIにおける大規模プロジェクトについて詳しく説明します。

4月2日(水)

Registration Open8:00 am

Recommended Pre-Conference Workshops and Symposia*9:00 am

On Wednesday, April 2, 2025, Cambridge Healthtech Institute is pleased to offer five pre-conference Workshops scheduled across two time slots (9:00 am–12:00 pm and 1:15–4:15 pm) and three Symposia from 9:00 am–4:20 pm. All are designed to be instructional, interactive, and provide in-depth information on a specific topic. They allow for one-on-one interaction and provide a great way to explain more technical aspects that would otherwise not be covered during the main conference tracks that take place Thursday–Friday.

*Separate registration required. See details on the Symposia here and details on the Workshops here.

4:40 pm

Organizer's Remarks

Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute

4:45 pm Talk Title to be Announced

Speaker to be Announced, CLOVERTEX

4:55 pm PLENARY KEYNOTE PRESENTATION:

From Bytes to Breakthroughs: Generative AI Driving the Future of Life Sciences and Healthcare

Sofia Guerra, Vice President, Bessemer Venture Partners

Subha Madhaven, Vice President and Head, AI/ML, Quantitative and Digital Sciences, Global Metrics and Data Management, Pfizer Inc.

Generative AI has the potential to transform life sciences and deliver unprecedented insights, automation, and efficiency. But is it? This keynote panel brings together leaders from biopharma, healthcare, and emerging tech who are leveraging AI to advance drug discovery, diagnostics, and patient care. Panelists will share their own case studies and real-world applications and discuss how they’ve tackled challenges—both technical and cultural. Look beyond the hype curve to see how this technology is really being used now and where the next opportunities lie.

Welcome Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)6:10 pm

The Bio-IT Kickoff Reception is a reunion—reconnect with friends, explore cutting-edge research, and celebrate innovation! Enjoy poster presentations, networking, and vote for the Best of Show and Poster awards.

Close of Day7:25 pm

4月3日(木)

Registration Open7:00 am

8:00 am

Organizer's Remarks

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News

8:05 am Talk Title to be Announced

Speaker to be Announced, Snowflake Computing Inc

AI-POWERED PLATFORMS IN DRUG DISCOVERY: TACKLING ANTIBIOTIC RESISTANCE AND AGING THERAPEUTICS
創薬におけるAI活用のプラットフォーム:抗生剤耐性と老化治療への取り組み

8:15 am PLENARY KEYNOTE PRESENTATION:

Deep Learning for Antibiotic Discovery

James J. Collins, PhD, Termeer Professor, Medical Engineering & Science, Massachusetts Institute of Technology

In this presentation, we highlight the Antibiotics-AI Project, which is a multi-disciplinary, innovative research program that is leveraging MIT's strengths in artificial intelligence, bioengineering, and the life sciences to discover and design novel classes of antibiotics. The Antibiotics-AI Project is focused on developing, integrating, and implementing deep learning models and chemogenomic screening approaches: (1) to predict novel antibiotics from expansive chemical libraries with diverse properties, (2) to design de novo novel antibiotics based on learned structural and functional properties of existing and newly discovered antibiotics, and (3) to identify, using explainable deep learning models, the chemical structures and molecular mechanisms underlying the newly discovered and/or designed antibiotics. With these deep learning approaches, we are utilizing multi-scale computation to embrace and harness the complexity of biology and chemistry, so as to discover, design, and develop new classes of antibiotics, up through preclinical studies. Our platform has been designed so that it can be utilized and applied in a rapid fashion to emerging and re-emerging bacterial pathogens, including multidrug-resistant (MDR) bacteria and extensively drug-resistant (XDR) bacteria.

8:45 am PLENARY KEYNOTE PRESENTATION:

Generative AI, Aging Research and Robotics as a Platform for Drug Discovery: From Hype to Clinical Efficacy

Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine

9:15 amSession Q&A

Coffee Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)9:30 am

Start your morning with coffee, connections, and cutting-edge research! Enjoy poster presentations, network in the Exhibit Hall, vote for awards, and a chance at a fabulous raffle prize!

Organizer's Welcome Remarks10:15 am

DRIVING CHANGE THROUGH SIMPLIFIED SYSTEM LANDSCAPES: FINDING VALUE BEYOND THE HYPE
簡素化されたシステム情勢による変化の推進:誇大宣伝を超えた価値の発見

Chairperson's Remarks (Sponsorship Opportunity Available)10:20 am

10:25 am

Too Many Clunky Systems? How to Successfully Manage Size, Complexity, and Cost of Your Pharma R&D System Landscape

Angelika Fuchs, Chapter Lead Data Products and Platforms, pRED Data & Analytics, Roche Diagnostics GmbH

With the increase of digitalization in Pharma R&D, increasingly large and complex system landscape have been established to address the manifold research use cases and processes. As a consequence, Pharma companies struggle with the exploded operative effort of their system landscapes limiting the potential for further innovation. In this talk, ongoing efforts and learnings around system landscape consolidation at Roche will be presented. On the example of molecule registration systems, concrete recommendations will be summarized how to approach the assessment and implementation of consolidating a specific business capability. At the same time, wrong assumptions and potential pitfalls around landscape harmonization will be shared with the audience.

10:55 am

Architecture as the Driver of System Change—And a Lesson in Change Management

Anthony Rowe, PhD, Head, Technology—Global Scientific IT, Johnson & Johnson Technology

11:25 am PANEL DISCUSSION:

Pharma Knowledge Graphs and Large Language Models: How Semantic Is Biomedical AI in 2025

PANEL MODERATOR:

Tom Plasterer, PhD, Managing Director, Life Sciences Innovation, ExponentL Data

Over the last year, synergies between language models and knowledge graphs have become more common and are being reduced to practice in many life science organizations. A new challenge—optimizing where AI excels while recognizing where humans should lead—has arisen. Semantics can be a bridge, structured as FAIR data, often materialized in knowledge graphs. In year three, the panel will debate the role of semantics and the “jagged frontier of AI,” touching upon Graph RAG, Agentic AI, and leveling-up the data-information-knowledge-wisdom pyramid.

PANELISTS:

Ben Busby, PhD, Director, Solution Science, DNAnexus, Inc.

Helena Deus, PhD, Lead for Semantic Data Products, Bristol Myers Squibb Co.

Brian Martin, Chief AI Product Owner, BTS; Head of AI, R&D Information Research; Senior Research Fellow, AbbVie, Inc.

11:55 am Talk Title to be Announced

Speaker to be Announced, ZS Associates

12:25 pm

Revolutionizing Drug Discovery Research with a Data-Driven SaaS Approach

Chris Stumpf, Director, Drug Discovery Informatics Solutions, Revvity Signals

This presentation explores how a new, cloud native SaaS platform enhances drug discovery by integrating the Make-Test-Decide R&D cycle into a single, user-friendly solution. By facilitating collaboration across diverse scientific domains and geographies, it enables researchers to discover hits and optimize lead compounds by simplifying the data-driven decision process. Learn how this comprehensive SaaS solution transforms drug development, streamlines workflows, and empowers researchers to focus more on science and less on disparate tools.

Session Break and Transition to Lunch12:55 pm

1:05 pm Talk Title to be Announced

Speaker to be Announced, Dotmatics Ltd

Refreshment Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)1:35 pm

Bio-IT's hall is bigger than ever—one break won’t cut it! Enjoy dessert and coffee after lunch, explore booths and posters, vote for awards, and participate in our raffle for a chance to win a prize!

CROSS-DEPARTMENTAL DATA SHARING AND COLLABORATIVE PLATFORMS
部門間のデータ共有と共同プラットフォーム

Chairperson's Remarks (Sponsorship Opportunity Available)2:25 pm

2:30 pm

Enabling Secondary Research with Clinical Trial Data: A Case Study in Cross-Departmental Data Harmonization

Radhesh Nair, Director, Data Science and Analytics, Clinical Development, AbbVie

This talk will discuss establishing the business value of pooling and sharing clinical study data across functions, as well as the impact of that data harmonization. We will explore how historical clinical trial data can be used to test hypotheses and generate insights, as well as address data privacy and ethics concerns.

3:00 pm

BioRels' Data Infrastructure: A Scientific Schema and Exchange Standard to Transform and Enhance Biological Data Sciences

Jeremy Desaphy, PhD, Director Scientific Data & Informatics, Genetic Medicines, Eli Lilly & Company

With the growing number of public resources available, data preparation remains a challenging and time-consuming exercise for scientists. BioRels is an open-source fully tunable data preparation infrastructure processing 30 of the main drug discovery resources. We will present this infrastructure and its impact on Lilly Genetic Medicines drug design. We will also show how complex and heterogenous data can easily be shared between BioRels systems and what the future can look like if we expand it as a community.

3:30 pm

Target Gene Notebook: A Collaborative Platform for Pursuing Project Targets

Jennifer Heymont, PhD, Associate Director, Scientific Informatics, Eisai, Inc.

Eisai’s Target Gene Notebook serves two primary functions. Firstly, it automates the collection of data from various informatics resources. Secondly, it offers a toolkit for subject-matter experts to compile and analyze this data, transforming it into actionable reports. These activities provide key genetic evidence for project target selection and safety evaluation.

4:00 pm Talk Title to be Announced

Speaker to be Announced, Nurocor

Best of Show Awards Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)4:30 pm

Unwind with colleagues at our lively reception! Explore posters, vote for the best, network with exhibitors, enjoy a drink, and try to win a raffle prize. Celebrate Best of Show winners!

Close of Day5:45 pm

4月4月(金)

Registration Open7:00 am

Quick Bytes & Networking Breakfast—Lifted Rooftop Restaurant & Bar (Sponsorship Opportunity Available)7:00 am

Start your morning with ‘Quick Bytes & Networking’! Enjoy a cozy restaurant-style setting, quick bites, and speed networking. Connect, converse, and energize your Bio-IT experience before the plenary keynote!

8:00 am

Organizer's Remarks

Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute

8:05 am

Innovative Practices Awards: Excellence in Technological Innovation

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News

The Innovative Practices Awards recognizes and celebrates technology innovation in the life sciences. Bio-IT World is currently accepting entries for the 2025 Innovative Practices Awards, a competition designed to recognize partnerships and projects pushing our industry forward. Winners will be announced in mid-March 2025, recognized during the Friday, April 4 Plenary Keynote Program, and scheduled to give a podium presentation about their project during the conference. For more details about the Awards and to submit an application, visit www.bioitworldexpo.com/innovativepractices.

8:20 am Talk Title to be Announced

Speaker to be Announced, Illumina

ADVANCING DRUG DISCOVERY AND HEALTHCARE THROUGH DATA-DRIVEN INNOVATION: FROM GENOMICS TO THERAPEUTICS
データドリブンのイノベーションによる創薬とヘルスケアの進歩:ゲノミクスから治療まで

8:30 am PLENARY KEYNOTE PRESENTATION:

Scaling Genomic Medicine: Transforming Newborn Screening through Informatics and Innovation

Robert C. Green, MD, MPH, Professor and Director of Genomes2People Research, Mass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School

The BabySeq Project has pioneered the integration of genomic sequencing into newborn and childhood screening, uncovering unexpected risk variants and transforming healthcare delivery. This keynote explores the groundbreaking progress in genomic medicine, featuring real-world stories of families impacted by these discoveries. Learn about the informatics challenges and innovative solutions required to scale genomic screening for national and global implementation, reshaping the future of precision medicine.

9:00 am PLENARY KEYNOTE PRESENTATION:

Unlocking the Power of Machine Learning and Data-at-Scale to Deliver with Speed the Best Therapeutic Candidates

Justin M. Scheer, PhD, Vice President In Silico Discovery & Head, Molecular Computational Team, Johnson & Johnson Innovative Medicine

The challenges of high costs, lengthy timelines, and significant attrition have prompted our industry to integrate AI/ML into all aspects of the business. This presentation highlights J&J's strategic investments in AI/ML technologies to enhance the drug discovery processes, including molecule design and optimization. By investing in these technologies with a modality agnostic approach, J&J aims to tackle the hardest targets in drug discovery, ultimately increasing the success rate of delivering better molecules faster.

9:30 amSession Q&A

Coffee Break in the Exhibit Hall with Poster Competition Winners Announced (Sponsorship Opportunity Available)9:45 am

Bio-IT is all about connections! Explore booths, award-winning posters, and network with clients, colleagues, and exhibitors. Grab coffee, build relationships, and stay for a chance to win a raffle prize!

Organizer's Remarks10:30 am

THE LAB OF THE FUTURE: CASE STUDIES IN CREATING DECISION-MAKING OPPORTUNITIES IN REAL TIME
将来のラボ:リアルタイムで意思決定の機会を生み出すケーススタディ

Chairperson's Remarks (Sponsorship Opportunity Available)10:35 am

10:40 am

Secondary Use of Data: Can It Be Leveraged on a Global Scale?

Christina T. Lu, Executive Director & Global Head Data Curation & Integration, Pharma Development Data Sciences, Genentech, Inc.

11:10 am

Enabling Automated End-to-End Chromatographic Data Workflows and Accelerated Data Insights with the Allotrope Simple Model (ASM) Vendor-Neutral Data Format

W. Christopher Siegler, PhD, Associate Director, Technical Product Management, MRL IT, Merck

Today’s R&D laboratory generates vast amounts of diverse data acquired with heterogeneous hardware and software solutions supplied by various vendors. The heterogeneity in vendor data formats and the need to connect data from multiple sources makes scientist daily workflows challenging. This presentation will demonstrate how Allotrope Simple Model (ASM) standardization of chromatographic data at scale simplifies technical architecture to improve scalability and creates transformative opportunities for on demand data consumption (visualizations, feed AI/ML pipelines, etc.).

11:40 am

Unified Namespace for Preclinical Manufacturing & Process Development: An Industry 4.0 Digitalization Platform for Real-Time Automated Decision-Making

Matthew Conway, Data Engineering Lead, Preclinical Manufacturing & Process Development, Regeneron Pharmaceuticals

Angela Hill, Lead OT Data Manager, PMPD, Regeneron Pharmaceuticals, Inc.

The implementation of a hub-and-spoke Unified Namespace can simplify lateral and vertical system integrations across the data ecosphere, connecting applications to make data available when and where needed irrespective of source. By changing the way we connect systems and applications, we are realizing our vision of a highly connected plant where data-driven, automated decisions drive operations in real-time.

12:10 pm Talk Title to be Announced

Speaker to be Announced, L7 Informatics Inc

12:40 pm Talk Title to be Announced

Speaker to be Announced, Illumina

Session Break and Transition to Lunch1:10 pm

Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own1:20 pm

Refreshment Break in the Exhibit Hall with Last Chance for Poster Viewing (Sponsorship Opportunity Available)1:50 pm

Feeling tired? Recharge during the final Networking Exhibit Hall break! Visit booths, explore posters, connect with peers, and turn in your Game Cards for a chance to win a raffle prize.

DRIVING AI INNOVATION: BEST PRACTICES FOR IMPLEMENTATION IN BIOPHARMA
AIイノベーションの推進:バイオファーマにおける導入のベストプラクティス

Chairperson's Remarks (Sponsorship Opportunity Available)2:30 pm

2:35 pm

Unlocking AI Potential: Best Practices for Implementation and Management

Vinod Das, Associate Director, Bayer Pharmaceuticals

Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada

Srivatsan Nagaraja, Founder, Vidya Seva

As AI transforms drug discovery, development, and precision medicine, understanding the business operations behind these advancements is essential. This session will cover critical aspects such as AI tool selection, project scoping, budget management, and prioritization amid evolving regulations. Gain insights from real-world case studies on successful AI deployment, with strategies to navigate regulatory risks while ensuring cost-effectiveness. Join us for a dynamic discussion to harness AI’s full potential in life sciences innovation.

Close of Conference4:05 pm

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


会議の詳細はこちらをご参照ください